Frontiers in HIV-1 Therapy: fourth conference of the NIAID National Cooperative Drug Discovery Groups-HIV
Related Experiment Videos
N Sarver1, R J Black, S Bridges
1Developmental Therapeutics Branch, National Institute of Allergy and Infectious Disease, Bethesda, MD.
Abstract:
This summary describes current studies in antiviral targeting as reported at the Frontiers in HIV Therapy conference, November 3-7, 1991, in San Diego, California. In parallel with the progressive steps in HIV-1 replication, the meeting covered potential antiviral targets starting from the time HIV-1 docks with the CD4 receptor to virus release. The summary concludes with current research trends to block HIV-1 growth.
Insights
This summary covers antiviral strategies against Human Immunodeficiency Virus type 1 (HIV-1) replication, from initial cell docking to virus release. Research trends focus on blocking HIV-1 growth through targeted interventions.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- The conference summarized research on Human Immunodeficiency Virus type 1 (HIV-1) replication.
- Studies focused on potential antiviral targets throughout the HIV-1 life cycle.
Framework:
- Antiviral targeting strategies were discussed, commencing from HIV-1's attachment to the CD4 receptor.
- The scope extended to all stages of HIV-1 replication up to viral release.
Implementation:
- The meeting highlighted progress in identifying and validating molecular targets for antiviral drug development.
- Research explored interventions at various stages of the viral replication cycle.
Implications:
- Current research trends aim to inhibit HIV-1 replication and viral load.
- Findings inform the development of novel therapeutic approaches for HIV/AIDS treatment.